PET/CT定义的肺癌隐匿性淋巴结转移患者预后良好并从辅助治疗中获益:一项多中心研究
该多中心研究纳入3537例接受手术切除的非小细胞肺癌患者,比较PET/CT定义的隐匿性淋巴结转移(ONM)与明显淋巴结转移的预后,以及ONM患者接受与未接受辅助治疗的生存差异。结果显示ONM在病理N1和N2患者中均为有利预后因素,且ONM患者接受辅助治疗可获得额外生存获益。
要点
- PET/CT定义的隐匿性淋巴结转移(ONM)在病理N1和N2非小细胞肺癌中均为有利预后因素。
- ONM患者接受辅助治疗较未接受者5年OS和RFS均更优。
- 研究共纳入3537例接受手术切除的非小细胞肺癌患者。
核心结论
- PET/CT定义的ONM识别出肺癌的一种独特临床亚型,ONM在病理N1或N2非小细胞肺癌中均为有利预后因素,辅助治疗可为ONM患者提供额外生存获益。
研究设计与样本
- 多中心研究,共纳入3537例接受手术切除的非小细胞肺癌患者,比较ONM与明显淋巴结转移患者的预后,以及ONM患者接受与未接受辅助治疗的预后。
主要发现
- N1患者中,ONM组5年OS为56.8% vs 明显淋巴结转移组52.3%(校正P=0.267),5年RFS为44.7% vs 33.2%(校正P=0.031)。
- N2患者中,ONM组5年OS为42.8% vs 明显淋巴结转移组32.3%(校正P=0.010),5年RFS为31.3% vs 21.6%(校正P=0.025)。
- ONM人群中,接受辅助治疗者5年OS为50.1% vs 未接受辅助治疗者33.5%(校正P<0.001),5年RFS为38.4% vs 22.1%(校正P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the surgical prognosis and efficacy of adjuvant therapy in non-small cell lung cancer (NSCLC) with occult lymph node metastasis (ONM) defined by positron emission tomography/computed tomography (PET/CT). METHODS: A total of 3537 NSCLC patients receiving surgical resection were included in this study. The prognosis between patients with ONM and evident nodal metastasis, ONM patients with and without adjuvant therapy was compared, respectively. RESULTS: ONM was associated with significantly better prognosis than evident nodal metastasis whether for patients with N1 (5-year OS: 56.8% versus 52.3%, adjusted p value = 0.267; 5-year RFS: 44.7% versus 33.2%, adjusted p value = 0.031) or N2 metastasis (5-year OS: 42.8% versus 32.3%, adjusted p value = 0.010; 5-year RFS: 31.3% versus 21.6%, adjusted p value = 0.025). In ONM population, patients receiving adjuvant therapy yielded better prognosis comparing to those without adjuvant therapy (5-year OS: 50.1% versus 33.5%, adjusted p value < 0.001; 5-year RFS: 38.4% versus 22.1%, adjusted p value < 0.001). CONCLUSIONS: ONM defined by PET/CT identifies a unique clinical subtype of lung cancer, ONM is a favorable prognostic factor whether for pathological N1 or N2 NSCLC and adjuvant therapy could provide additional survival benefits for ONM patients.
引用
- Deng J, Zhong Y, Wang T, et al. Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study. Eur J Nucl Med Mol Imaging. 2022. PMID: 35048154. doi:10.1007/s00259-022-05690-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。